|
Webinar: Monkeypox Update with MDHHS, MHA and the MOA
MOA joined MDHHS and MHA for — "What you need to know about Monkeypox Webinar"
The MOA would like to thank our presenters, Dr. Natasha Bagdasarian, Dr. Nick Gilpin, and Joe Coyle, for participating in the Monkeypox Update lunchtime webinar.
Speakers
 |
Natasha Bagdasarian, MD, MPH, FIDSA
Dr. Natasha Bagdasarian is the chief medical executive for the State of Michigan. She provides overall medical guidance for Michigan as a cabinet member of the Governor. She is board certified by the American Board of Internal Medicine in both internal medicine and infectious diseases and is a Fellow of the Infectious Diseases Society of America.
Dr. Natasha Bagdasarian Presentation: Monkeypox Virus (MPV) Update (PDF)
|
 |
Nick Gilpin, DO
Dr. Nick Gilpin is an infectious disease physician with Beaumont Health. He currently serves as the Medical Director of Infection Prevention for Beaumont Royal Oak, and he is also the Medical Director for Infection Prevention for the Beaumont Health System.
Dr. Nick Gilpin Presentation: Monkeypox: Clinical Overview (PDF)
|
 |
Joseph R. Coyle, MPH
Director of the Bureau of Infectious Disease Prevention, MDHHS
Joseph Coyle is the Director of the Bureau of Infectious Disease Prevention at the Michigan Department of Health & Human Services and has been with MDHHS since 2011.
Joseph Coyle Presentation: Monkeypox Testing Basics (PDF)
|
Updates on Monkeypox (MPV) and COVID-19
The Michigan Osteopathic Association participated in a Michigan Department of Health and Human Services (MDHHS) conference on updates for healthcare providers on the current status of MPV and COVID-19 response in Michigan.
Here is a quick list of online resources:
MDHHS Updates on Monkeypox (MPV)
Monkeypox (MPV) information page
Monkeypox Resources for Health Care Professionals
CDC
Monkeypox 2022 Outbreak Cases & Data
MDHHS Updates on COVID-19
On August 11, 2022, the Centers for Disease Control and Prevention (CDC) issued an update to the Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.
The update is outlined below:
Updated guidance on COVID-19 vaccination following exposure to SARS-CoV-2:
Recent exposure to SARS-COV-2 is not a contraindication or precaution to COVID-19 vaccination. People with a known or potential SARS-COV-2 exposure can receive vaccine if they do not have symptoms consistent with SARS-CoV-2 infection; however, people should follow CDC’s post-exposure guidance.
COVID-19 vaccines are not recommended for post-exposure prophylaxis. People should be informed that vaccination is to help prevent severe COVID-19 following future exposures. SARS-CoV-2 viral testing may be necessary to differentiate between common post-vaccination symptoms and symptoms of SARS-CoV-2 infection:
- People who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore throat, loss of taste or smell) should isolate and be evaluated for SARS-CoV-2 infection as soon as possible.
- People who develop signs and symptoms that could be from either COVID-19 vaccination or SARS-CoV-2 infection (e.g., fever, fatigue, headache, myalgia) without typical COVID-19 symptoms described above, and are clinically stable, should isolate and, if symptoms do not improve by two days post-vaccination, be evaluated for SARS-CoV-2 infection.
If you have any questions or concerns, please don’t hesitate in contacting MDHHS at [email protected]
|
